{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:52:05Z","timestamp":1791183125457,"version":"4.1.0"},"reference-count":40,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":277,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Prim Health Care Res Dev"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1463423626101868_as1\">\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>We aimed to examine changes in antidiabetic drug utilization associated with implementation and subsequent easing of pandemic-related restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1463423626101868_as2\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The COVID-19 pandemic and associated restrictions disrupted healthcare access and glycemic regulation, affecting diabetes management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1463423626101868_as3\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We collected nationwide outpatient antidiabetic drug sales and projected prescribing data from IQVIA Turkey between 01.03.2018 and 31.12.2022. We assessed average monthly consumption, expenditure, and quarterly prescribing trends across \u2018before restrictions\u2019 (BfR, 01.03.2018\u201331.03.2020), \u2018during restrictions\u2019 (DuR, 01.04.2020\u201331.03.2022), and \u2018after restrictions\u2019 (AfR, 01.04.2022\u201331.12.2022) periods. Consumption and prescribing levels were expressed as \u2018defined daily doses\/1,000 inhabitants\/day\u2019 (DID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1463423626101868_as4\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Antidiabetic consumption increased from 123.6 \u00b1 12.2 DID in BfR to 156.3 \u00b1 25.4 DID in DuR and remained elevated in AfR (151.2 \u00b1 28.9 DID), paralleled by expenditure (\u20ac63.6 m \u00b1 8.4 m, \u20ac85.1 m \u00b1 14.8 m, and \u20ac83.9 m \u00b1 19.1 m, respectively). Prescribing levels declined from BfR to DuR (56.4 \u00b1 3.5 to 29.9 \u00b1 3.6 DID,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and slightly recovered in AfR (46.0 \u00b1 10.9 DID,\n                      <jats:italic>p<\/jats:italic>\n                      &gt; 0.05 vs. earlier periods). Oral antidiabetic consumption rose from 71.2 \u00b1 6.8 DID in BfR to 90.6 \u00b1 17.2 DID in DuR (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and further to 96.9 \u00b1 19.4 DID in AfR (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001 vs. BfR), while sodium-glucose cotransporter-2 inhibitor use increased across periods (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Injectable antidiabetic consumption, mainly insulins, increased from BfR to DuR (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and decreased in AfR (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01 vs. DuR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1463423626101868_as5\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We demonstrated a sustained increase in antidiabetic consumption following implementation of COVID-19-related restrictions, persisting beyond easing of most measures. Medication-access policies, panic stockpiling, improved glycemic adherence, and newer therapies might have contributed. These findings may inform strategies to strengthen family physician-community pharmacist coordination while maintaining treatment continuity and optimizing medication access during future public health emergencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s1463423626101868","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:16:58Z","timestamp":1791181018000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Population-based trends in antidiabetic medication utilization during the COVID-19 pandemic: results from the PANDUTI-TR study"],"prefix":"10.1017","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9558-1914","authenticated-orcid":false,"given":"Caner","family":"Vizdiklar","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kswqa67","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, Marmara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-6349","authenticated-orcid":false,"given":"Volkan","family":"Aydin","sequence":"additional","affiliation":[{"name":"School of Dentistry, Marmara University"},{"name":"Hypertension and Atherosclerosis Research Centre (HIPAM), Marmara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0737-9450","authenticated-orcid":false,"given":"Gokhan","family":"Tazegul","sequence":"additional","affiliation":[{"name":"School of Medicine, Marmara University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-0818","authenticated-orcid":false,"given":"Ahmet","family":"Akici","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kswqa67","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, Marmara University"},{"name":"Hypertension and Atherosclerosis Research Centre (HIPAM), Marmara University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"S1463423626101868_ref17","doi-asserted-by":"publisher","DOI":"10.3390\/nu13114122"},{"key":"S1463423626101868_ref32","unstructured":"Turkish Medicines and Medical Devices Agency (2020) Announcement to pharmacists and all concerned parties [in turkish]. Available at https:\/\/www.titck.gov.tr\/duyuru\/eczacilara-ve-tum-ilgililere-duyurulur-16032020090441 (accessed 26 January 2026)."},{"key":"S1463423626101868_ref21","unstructured":"MedCalc Software Ltd (2024) Comparison of correlation coefficients. Version 22.020. Available at https:\/\/www.medcalc.org\/calc\/comparison_of_correlations.php (accessed 15 February 2026)."},{"key":"S1463423626101868_ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14771"},{"key":"S1463423626101868_ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04310-9"},{"key":"S1463423626101868_ref14","volume-title":"IDF Diabetes Atlas","year":"2025"},{"key":"S1463423626101868_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102345"},{"key":"S1463423626101868_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/puh2.131"},{"key":"S1463423626101868_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107382"},{"key":"S1463423626101868_ref26","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092826"},{"key":"S1463423626101868_ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09057-8"},{"key":"S1463423626101868_ref9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Diseases and injuries, global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the global burden of disease study 2019","volume":"396","author":"Abbas","year":"2020","journal-title":"Lancet"},{"key":"S1463423626101868_ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819900258"},{"key":"S1463423626101868_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2024.101000"},{"key":"S1463423626101868_ref13","volume-title":"IDF Diabetes Atlas","year":"2021"},{"key":"S1463423626101868_ref40","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70336"},{"key":"S1463423626101868_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-022-00912-2"},{"key":"S1463423626101868_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2022.02.002"},{"key":"S1463423626101868_ref4","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"S1463423626101868_ref22","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13030322"},{"key":"S1463423626101868_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"S1463423626101868_ref36","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2025.2455383"},{"key":"S1463423626101868_ref33","unstructured":"Turkish Medicines and Medical Devices Agency (2022) Attention all companies [in Turkish]. Available at https:\/\/www.titck.gov.tr\/duyuru\/tum-firmalarin-dikkatine-14122022164251 (accessed 29 January 2026)."},{"key":"S1463423626101868_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-022-03001-5"},{"key":"S1463423626101868_ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"S1463423626101868_ref31","doi-asserted-by":"publisher","DOI":"10.56016\/dahudermj.1801645"},{"key":"S1463423626101868_ref39","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmaf072"},{"key":"S1463423626101868_ref35","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2024) ATC classification index with DDDs. Available at https:\/\/atcddd.fhi.no\/atc_ddd_index_and_guidelines\/guidelines\/ (accessed 14 December 2024)."},{"key":"S1463423626101868_ref10","volume-title":"Survey of Socio-Economic Development Ranking of Provinces and Regions (SEDI-2017) [in Turkish]","year":"2019"},{"key":"S1463423626101868_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00358-y"},{"key":"S1463423626101868_ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-024-02326-3"},{"key":"S1463423626101868_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.06.042"},{"key":"S1463423626101868_ref5","doi-asserted-by":"publisher","DOI":"10.17826\/cumj.681368"},{"key":"S1463423626101868_ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1170156"},{"key":"S1463423626101868_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"S1463423626101868_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z"},{"key":"S1463423626101868_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13171"},{"key":"S1463423626101868_ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031095"},{"key":"S1463423626101868_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"S1463423626101868_ref29","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S420545"}],"container-title":["Primary Health Care Research &amp; Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1463423626101868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:17:00Z","timestamp":1791181020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1463423626101868\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S1463423626101868"],"URL":"https:\/\/doi.org\/10.1017\/s1463423626101868","relation":{},"ISSN":["1463-4236","1477-1128"],"issn-type":[{"value":"1463-4236","type":"print"},{"value":"1477-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e120"}}